Research programme: angiogenesis inhibitors - IVAX Drug Research Institute
Latest Information Update: 05 Jul 2007
At a glance
- Originator IVAX Drug Research Institute
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Sep 2001 The Institute for Drug Research is now called the IVAX Drug Research Institute
- 02 Oct 2000 Preclinical development for Cancer in Hungary (unspecified route)